ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).

被引：0

作者：

Lonial, Sagar

Richardson, Paul Gerard Guy

Moreau, Philippe

Orlowski, Robert Z.

San-Miguel, Jesus F.

Dimopoulos, Meletios A.

Palumbo, Antonio Pierangelo

Facon, Thierry

Vij, Ravi

White, Darrell

Reece, Donna Ellen

Singhal, Anil

Kroog, Glenn Scott

Kopit, Justin

Anderson, Kenneth Carl

机构：

[1] Multiple Myeloma Res Consortium, Norwalk, CT USA

[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Univ Hosp, Nantes, France

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Hosp Univ Salamanca, Salamanca, Spain

[7] Hellen Cooperat Oncol Grp, Athens, Greece

[8] Univ Turin, Turin, Italy

[9] Hop Claude Huriez, Lille, France

[10] Washington Univ, Sch Med, St Louis, MO USA

[11] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[12] Princess Margaret Hosp, Program Multiple Myeloma, Toronto, ON M4X 1K9, Canada

[13] Abbott Biotherapeut, Redwood City, CA USA

[14] Bristol Myers Squibb Co, Global Clin Res Oncol, Princeton, NJ USA

[15] Bristol Myers Squibb Co, Princeton, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8112

引用

页数：1

共 50 条

[41] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma. [J].

San Miguel, Jesus ;

Raab, Marc S. ;

Goldschmidt, Hartmut ;

Lonial, Sagar ;

Richardson, Paul G. ;

Shelat, Suresh ;

Bleickardt, Eric W. ;

Palumbo, Antonio .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[42] Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial [J].

Dimopoulos, Meletios A. ;

Richardson, Paul G. ;

Bahlis, Nizar J. ;

Grosicki, Sebastian ;

Cavo, Michele ;

Beksac, Meral ;

Legiec, Wojciech ;

Liberati, Anna M. ;

Goldschmidt, Hartmut ;

Belch, Andrew ;

Magen, Hila ;

Larocca, Alessandra ;

Laubach, Jacob P. ;

Petrucci, Maria T. ;

Reece, Donna ;

White, Darrell ;

Mateos, Maria-Victoria ;

Spicka, Ivan ;

Lazaroiu, Mihaela ;

Berdeja, Jesus ;

Kaufman, Jonathan L. ;

Jou, Ying-Ming ;

Ganetsky, Alex ;

McKiver, Mihaela Popa ;

Lonial, Sagar ;

Weisel, Katja .

LANCET HAEMATOLOGY, 2022, 9 (06) :E403-E414

[43] Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial [J].

Dimopoulos, Meletios A. ;

Lonial, Sagar ;

Betts, Keith A. ;

Chen, Clara ;

Zichlin, Miriam L. ;

Brun, Alexander ;

Signorovitch, James E. ;

Makenbaeva, Dinara ;

Mekan, Sabeen ;

Sy, Oumar ;

Weisel, Katja ;

Richardson, Paul G. .

CANCER, 2018, 124 (20) :4032-4043

[44] Phase 3 ELOQUENT-2 study extended 5-y follow-up comparing elotuzumab plus lenalidomide/dexamethasone (ELd) with Ld to treat relapsed/refractory multiple myeloma [J].

Weisel, K. ;

Dimopoulos, M. A. ;

Lonial, S. ;

White, D. ;

Moreau, P. ;

Mateos, M-, V ;

San Miguel, J. ;

Anderson, K. ;

Shpilberg, O. ;

Grosicki, S. ;

Spicka, I ;

Walter-Cronek, A. ;

Magen, H. ;

Belch, A. ;

Reece, D. ;

Beksac, M. ;

Shelat, S. G. ;

Mekan, S. ;

Sy, O. ;

Singhal, A. K. ;

Richardson, P. G. .

ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 :230-230

[45] Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial [J].

Dimopoulos, Meletios A. ;

Oriol, Albert ;

Nahi, Hareth ;

San-Miguel, Jesus ;

Bahlis, Nizar J. ;

Usmani, Saad Z. ;

Rabin, Neil ;

Orlowski, Robert Z. ;

Suzuki, Kenshi ;

Plesner, Torben ;

Yoon, Sung-Soo ;

Ben Yehuda, Dina ;

Richardson, Paul G. ;

Goldschmidt, Hartmut ;

Reece, Donna ;

Ahmadi, Tahamtan ;

Qin, Xiang ;

Mayo, Wendy Garvin ;

Gai, Xue ;

Carey, Jodi ;

Carson, Robin ;

Moreau, Philippe .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08) :1590-+

[46] Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial [J].

Siegel, David S. ;

Schiller, Gary J. ;

Samaras, Christy J. ;

Sebag, Michael ;

Berdeja, Jesus G. ;

Ganguly, Siddhartha ;

Matous, Jeffrey V. ;

Song, Kevin W. ;

Seet, Christopher S. ;

Acosta-Rivera, Mirelis ;

Bar, Michael ;

Quick, Donald P. ;

Anz, Bertrand M., III ;

Fonseca, Gustavo A. ;

Reece, Donna E. ;

Lee, Kim ;

Chung, Weiyuan ;

Agarwal, Amit ;

Bahlis, Nizar J. .

BLOOD, 2020, 136

[47] Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). [J].

Lonial, Sagar ;

Dimopoulos, Meletios A. ;

Weisel, Katja C. ;

White, Darrell ;

Moreau, Philippe ;

Mateos, Maria-Victoria ;

Miguel, Jesus San ;

Anderson, Kenneth Carl ;

Shpilberg, Ofer ;

Grosicki, Sebastian ;

Spicka, Ivan ;

Walter-Croneck, Adam ;

Magen, Hila ;

Belch, Andrew ;

Reece, Donna Ellen ;

Beksac, Meral ;

Mekan, Sabeen ;

Sy, Oumar ;

Singhal, Anil K. ;

Richardson, Paul G. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[48] Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM) [J].

Lonial, Sagar ;

Dimopoulos, Meletios ;

Weisel, Katja ;

White, Darrell ;

Moreau, Philippe ;

Mateos, Maria-Victoria ;

San Miguel, Jesus ;

Anderson, Kenneth ;

Shpilberg, Ofer ;

Grosicki, Sebastian ;

Spicka, Ivan ;

Walter-Croneck, Adam ;

Magen, Hila ;

Belch, Andrew ;

Reece, Donna ;

Beksac, Meral ;

Shelat, Suresh ;

Sy, Oumar ;

Singhal, Anil ;

Richardson, Paul .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 :S253-S253

[49] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial [J].

Richardson, Paul G. ;

Oriol, Albert ;

Beksac, Meral ;

Liberati, Anna Marina ;

Galli, Monica ;

Schjesvold, Fredrik ;

Lindsay, Jindriska ;

Weisel, Katja ;

White, Darrell ;

Facon, Thierry ;

Miguel, Jesus Son ;

Sunami, Kazutaka ;

O'Gorman, Peter ;

Sonneveld, Pieter ;

Robak, Pawel ;

Semochkin, Sergey ;

Schey, Steve ;

Yu, Xin ;

Doerr, Thomas ;

Bensmaine, Amine ;

Biyukov, Tsvetan ;

Peluso, Teresa ;

Zaki, Mohamed ;

Anderson, Kenneth ;

Dimopoulos, Meletios .

LANCET ONCOLOGY, 2019, 20 (06) :781-794

[50] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma [J].

Shinsuke Iida ;

Tohru Izumi ;

Takuya Komeno ;

Yasuhito Terui ;

Takaaki Chou ;

Takashi Ikeda ;

Deborah Berg ;

Shinichi Fukunaga ;

Kenkichi Sugiura ;

Makoto Sasaki .

International Journal of Clinical Oncology, 2022, 27 :224-233

← 1 2 3 4 5 →